The glycolipid sulfatide protects insulin-producing cells against cytokine-induced apoptosis, a possible role in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 8, 2010, Pages 631-638

  Roeske Nielsen, A ^a   Dalgaard, L T ^b   Mansson J E ^c   Buschard, K ^a  

^a Rigshospitalet   (Denmark)

^b ROSKILDE UNIVERSITY   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cell; Apoptosis; Cytokines; Diabetes; Glycosphingolipid; Nitric oxide; Sulfatide

Indexed keywords

CASPASE 3; CASPASE 7; CYTOKINE; DNA NUCLEOTIDYLEXOTRANSFERASE; GAMMA INTERFERON; GLYCOLIPID; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1BETA; NITRIC OXIDE; SULFATIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG INHIBITION; ENZYME ACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; NICK END LABELING; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SECRETORY GRANULE; STATISTICAL SIGNIFICANCE;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CHEMOKINE CCL2; CYTOKINES; DIABETES MELLITUS, TYPE 2; GLUCOSE; INSULIN-SECRETING CELLS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED LEW; RNA, MESSENGER; SULFOGLYCOSPHINGOLIPIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049461252     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1130     Document Type: Article

References (45)

1. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54(Suppl 2): S97-S107.
2. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-350.
3. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
4. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-1547.
5. Mandrup-Poulsen T, Bendtzen K, Nerup J, Egeberg J, Nielsen JH. Mechanisms of pancreatic islet cell destruction. Dose-dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy 1986; 41: 250-259.
6. Dinarello CA. Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 1997; 24:S9, S81-S93.
7. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999; 18: 6842-6844.
8. Auron PE. The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998; 9: 221-237.
9. Darville MI, Eizirik DL. Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia 1998; 41: 1101-1108.
10. Martin E, Nathan C, Xie QW. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med 1994; 180: 977-984.
11. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269: 4705-4708.
12. Bal-Price A, Brown GC. Nitric-oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondria. J Neurochem 2000; 75: 1455-1464.
13. +, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005; 54: 452-461.
14. Pirot P, Ortis F, Cnop M, et al. Transcriptional regulation of the endoplasmic reticulum stress gene chop in pancreatic insulin-producing cells. Diabetes 2007; 56: 1069-1077.
15. Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93: 4065-4074.
16. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T. Treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 2008; 44: 141-148.
17. Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-1110.
18. Somm E, Cettour-Rose P, Asensio C, et al. Interleukin=-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 387-393.
19. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
20. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54(Suppl 2): S108-S113.
21. Boni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008; 10(Suppl 4): 201-204.
22. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
23. Fredman P, Mansson JE, Rynmark BM, et al. The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling: possible involvement in insulin trafficking. Glycobiology 2000; 10: 39-50.
24. Osterbye T, Jorgensen KH, Fredman P, et al. Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 2001; 11: 473-479.
25. Buschard K, Diamant M, Bovin LE, Mansson JE, Fredman P, Bendtzen K. Sulphatide and its precursor galactosylceramide influence the production of cytokines in human mononuclear cells. APMIS 1996; 104: 938-944.
26. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 2004; 91: 205-211.
27. Buschard K, Schloot NC, Kaas A, et al. Inhibition of insulin-specific autoreactive T-cells by sulphatide which is variably expressed in beta cells. Diabetologia 1999; 42: 1212-1218.
28. +)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002; 51: 2514-2521.
29. Buschard K, Blomqvist M, Mansson JE, Fredman P, Juhl K, Gromada J. C16:0 sulfatide inhibits insulin secretion in rat beta-cells by reducing the sensitivity of KATP channels to ATP inhibition. Diabetes 2006; 55: 2826-2834.
30. Buschard K, Fredman P, Bog-Hansen E, et al. Low serum concentration of sulfatide and presence of sulfated lactosylceramid are associated with type 2 diabetes. The Skaraborg Project. Diabet Med 2005; 22: 1190-1198.
31. Rosengren B, Fredman P, Mansson JE, Svennerholm L. Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J Neurochem 1989; 52: 1035-1041.
32. Blomqvist M, Carrier M, Andrews T, et al. In vivo administration of the C16:0 fatty acid isoform of sulfatide increases pancreatic sulfatide and enhances glucose-stimulated insulin secretion in Zucker fatty (fa/fa) rats. Diabetes Metab Res Rev 2005; 21: 158-166.
33. Aaen K, Rygaard J, Josefsen K, et al. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990; 39: 697-701.
34. Kutlu B, Cardozo AK, Darville MI, et al. Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells. Diabetes 2003; 52: 2701-2719.
35. Li F, Mahato RI. iNOS gene silencing prevents inflammatory cytokine-induced beta-cell apoptosis. Mol Pharm 2008; 5: 407-417.
36. McCabe C, Samali A, O'brien T. Beta cell cytoprotective strategies: establishing the relative roles for iNOS and ROS. Biochem Biophys Res Commun 2006; 342: 1240-1248.
37. Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583: 9-24.
38. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 2002; 7: 335-345.
39. Shen W, Stone K, Jales A, Leitenberg D, Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol 2008; 180: 4425-4432.
40. Abboushi N, El-Hed A, El-Assaad W, et al. Ceramide inhibits IL-2 production by preventing protein kinase C-dependent NF-kappaB activation: possible role in protein kinase Ctheta regulation. J Immunol 2004; 173: 3193-3200.
41. + concentration. J Biol Chem 1998; 273: 33501-33507.
42. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
43. Takahashi A, Nagashima K, Hamasaki A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007; 77: 343-350.
44. + influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-1713.
45. Palmer JP, Helqvist S, Spinas GA, et al. Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 1989; 38: 1211-1216.